Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China

BMC Endocrine Disorders

Volumn 12, Issue , 2012, Pages

  Wang, Yu hong ^a   Lin, Yuan ^a   Xue, Ling ^a   Wang, Jin hui ^a   Chen, Min hu ^a   Chen, Jie ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Clinical pathological characteristics; Gastroenteropancreatic neuroendocrine neoplasms; Survival

Indexed keywords

CHROMOGRANIN A; SYNAPTOPHYSIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CHINA; DIGESTIVE SYSTEM CANCER; DISTANT METASTASIS; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASM; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIXED ADENOENDOCRINE CARCINOMA; NEUROENDOCRINE CARCINOMA; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS TUMOR;

EID: 84870059329     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-12-30     Document Type: Article

References (48)

1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9(1):61-72. 10.1016/S1470-2045(07)70410-2, 18177818.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003, 97(4):934-959. 10.1002/cncr.11105, 12569593.
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, et al. One hundred years after " carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26(18):3063-3072. 10.1200/JCO.2007.15.4377, 18565894.
4. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system 2010, Lyon: International Agency for Research on Cancer, 4.
5. Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm China Consensus Guidelines for the standards of histopathologic diagnosis in Gastroenteropancreatic Neuroendocrine neoplasm. Chin J Pathol 2011, 40(4):257-262. Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm.
6. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008, 113(10):2655-2664. 10.1002/cncr.23883, 18853416.
7. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V, Sevilla-Garcia I, Villabona-Artero C, Beguiristain-Gomez A, Llanos-Munoz M, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010, 21(9):1794-1803. 10.1093/annonc/mdq022, 20139156.
8. Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 2009, 90(4):349-363. 10.1159/000242109, 19776553.
9. Lepage C, Rachet B, Coleman MP. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 2007, 132(3):899-904. 10.1053/j.gastro.2007.01.006, 17383419.
10. Lim T, Lee J, Kim JJ, Lee JK, Lee KT, Kim YH, Kim KW, Kim S, Sohn TS, Choi DW, et al. Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea. Asia Pac J Clin Oncol 2011, 7(3):293-299. 10.1111/j.1743-7563.2011.01423.x, 21884442.
11. Li AF, Hsu CY, Li A, Tai LC, Liang WY, Li WY, Tsay SH, Chen JY. A 35-year retrospective study of carcinoid tumors in Taiwan: differences in distribution with a high probability of associated second primary malignancies. Cancer 2008, 112(2):274-283. 10.1002/cncr.23159, 18008361.
12. Konishi T, Watanabe T, Kishimoto J, Kotake K, Muto T, Nagawa H. Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years. Gut 2007, 56(6):863-868. 10.1136/gut.2006.109157, 1954860, 17213340.
13. Ito T, Tanaka M, Sasano H, Osamura YR, Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, et al. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 2007, 42(6):497-500. 10.1007/s00535-007-2056-6, 17671766.
14. Wang DS, Zhang DS, Qiu MZ, Wang ZQ, Luo HY, Wang FH, Li YH, Xu RH. Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas. Tumour Biol 2011, 32(4):697-705. 10.1007/s13277-011-0170-9, 21479734.
15. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004, 240(1):117-122. 10.1097/01.sla.0000129342.67174.67, 1356383, 15213627.
16. Van Gompel JJ, Sippel RS, Warner TF, Chen H. Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg 2004, 28(4):387-392. 10.1007/s00268-003-7019-3, 14994141.
17. Onaitis MW, Kirshbom PM, Hayward TZ, Quayle FJ, Feldman JM, Seigler HF, Tyler DS. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg 2000, 232(4):549-556. 10.1097/00000658-200010000-00010, 1421187, 10998653.
18. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gonen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010, 34(3):300-313. 10.1097/PAS.0b013e3181ce1447, 20118772.
19. Pape UF, Bohmig M, Berndt U, Tiling N, Wiedenmann B, Plockinger U. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center. Ann N Y Acad Sci 2004, 1014:222-233. 10.1196/annals.1294.025, 15153439.
20. Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, Ott MJ. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999, 229(6):815-821. discussion 822-813., 10.1097/00000658-199906000-00008, 1420828, 10363895.
21. Vinik AI, Thompson N, Eckhauser F, Moattari AR. Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. Acta Oncol 1989, 28(3):389-402. 10.3109/02841868909111212, 2663049.
22. Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000, 95(9):2271-2277. 10.1111/j.1572-0241.2000.02480.x, 11007228.
23. Zimmer T, Scherubl H, Faiss S, Stolzel U, Riecken EO, Wiedenmann B. Endoscopic ultrasonography of neuroendocrine tumours. Digestion 2000, 62(Suppl 1):45-50.
24. Varas Lorenzo MJ, Miquel Collell JM, Maluenda Colomer MD, Boix Valverde J, Armengol Miro JR. Preoperative detection of gastrointestinal neuroendocrine tumors using endoscopic ultrasonography. Rev Esp Enferm Dig 2006, 98(11):828-883.
25. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008, 100(18):1282-1289. 10.1093/jnci/djn275, 2538549, 18780869.
26. Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009, 90(2):162-166. 10.1159/000182196, 19060454.
27. Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, Rivkin SE, Fleming TR, Macdonald JS. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 1994, 73(5):1505-1508. 10.1002/1097-0142(19940301)73:5<1505::AID-CNCR2820730530>3.0.CO;2-V, 8111718.
28. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001, 91(8):1543-1548. 10.1002/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N, 11301403.
29. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005, 23(22):4897-4904. 10.1200/JCO.2005.03.616, 16051944.
30. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980, 303(21):1189-1194. 10.1056/NEJM198011203032101, 6252466.
31. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992, 326(8):519-523. 10.1056/NEJM199202203260804, 1310159.
32. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011, 117(2):268-275. 10.1002/cncr.25425, 20824724.
33. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991, 68(2):227-232. 10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I, 1712661.
34. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006, 24(22):3548-3554. 10.1200/JCO.2005.05.0575, 16877720.
35. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001, 92(5):1101-1107. 10.1002/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V, 11571721.
36. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999, 81(8):1351-1355. 10.1038/sj.bjc.6690325, 2362979, 10604732.
37. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004, 22(23):4762-4771. 10.1200/JCO.2004.04.024, 15570077.
38. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26(26):4311-4318. 10.1200/JCO.2008.16.7858, 2653122, 18779618.
39. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26(20):3403-3410. 10.1200/JCO.2007.15.9020, 18612155.
40. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27(28):4656-4663. 10.1200/JCO.2009.22.8510, 19704057.
41. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010, 28(1):69-76. 10.1200/JCO.2009.24.2669, 19933912.
42. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6):514-523. 10.1056/NEJMoa1009290, 21306238.
43. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6):501-513. 10.1056/NEJMoa1003825, 21306237.
44. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004, 15(6):966-973. 10.1093/annonc/mdh216, 15151956.
45. Karashima T, Cai RZ, Schally AV. Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release. Life Sci 1987, 41(8):1011-1019. 10.1016/0024-3205(87)90690-4, 2886886.
46. Oberg K. Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology 2004, 80(Suppl 1):57-61.
47. Faiss S, Rath U, Mansmann U, Caird D, Clemens N, Riecken EO, Wiedenmann B. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 1999, 60(5):469-476. 10.1159/000007693, 10473972.
48. Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, Skogseid B, Oberg KE, Eriksson BK. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol/European Federation of Endocrine Societies 2004, 151(1):107-112.